News Release

Printer Friendly Version View printer-friendly version
<< Back
Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons

Studies Assess Impact of EXPAREL on Postsurgical Pain and Health Economic Outcomes Following Total Knee and Hip Replacement Procedures

PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that data evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain following knee and hip arthroplasty (replacement) procedures will be presented at the 81st annual meeting of the American Academy of Orthopedic Surgeons (AAOS). The meeting will be held on March 11-15, 2014 at the Ernest N. Morial Convention Center in New Orleans. EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.

Abstract information, authors, schedule and presentation venue are listed below:

Poster

Presentation Title: Comparison of Infiltration with Long-acting Bupivacaine to a Femoral Nerve Catheter for Total Knee Replacement

Author (s): Roger H. Emerson, MD and John W. Barrington, MD (Texas Center for Joint Replacement, Plano, TX)

Session: P111-P205-Adult Reconstruction Knee Posters

Date/Time: Tuesday, March 11, 2014 at 8:00 a.m. - 3:00 p.m.

Location: Academy Hall

Posterboard No. P124

Podium

Presentation Title: Liposomal Bupivacaine: The First 1,000 Cases in a New Era

Author (s): John W. Barrington, MD and Roger H. Emerson, MD (Texas Center for Joint Replacement, Plano, TX)

Session: 661-675-Adult Reconstruction Knee VI

Date/Time: Friday, March 14, 2014 at 12:18-12:24 p.m.

Location: Theater A

Presentation No. 675

The AAOS 2014 meeting preliminary program is available online here.

About Pacira

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other products have utilized the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.

About EXPAREL®

EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.

Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.

Source: Pacira Pharmaceuticals, Inc.

Company Contact:
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574
Jessica.Cho@pacira.com
or
Media Contact:
Pure Communications, Inc.
Susan Heins, 864-286-9597
sjheins@purecommunicationsinc.com